<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03690440</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2017-09</org_study_id>
    <secondary_id>N° : 2018-A00092-53</secondary_id>
    <nct_id>NCT03690440</nct_id>
  </id_info>
  <brief_title>Study Describing the Coverage, Cares and the Fertility of Patients of Less Than 45 Years With a Borderline Ovarian Tumor</brief_title>
  <acronym>OPTIBOT</acronym>
  <official_title>OPTIBOT: Study Describing the Coverage, Cares and the Fertility of Patients of Less Than 45 Years With a Borderline Ovarian Tumor (BOT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective and prospective multi-center study

      Indication: Fertility-sparing surgery for patients with borderline ovarian tumor and
      fertility

      Objectives:

        -  Description of the characteristics of the patients of less than 45 years having a
           fertility-sparing surgery for borderline ovarian tumors, the modalities of care and
           their fertility.

        -  Validation of a nomogram as an information medium to the patients concerned on their
           chance of alive birth according to their personal characteristics

      Origin and nature of the specific data:

        -  Extraction from the database &quot; Tumeurs Malignes Rares de l'Ovaire &quot; (TMRO)

        -  Collection of retrospective further informations in the participating centers

        -  Data collection from the patients (questionnaires) The data will be identified by the
           TMRO number allocated to every participant of the TMRO study .

      Data traffic :

      TMRO database extraction for the patients with BOT and corresponding to the inclusion
      criteria, supplied by Arcagy-Gineco.

      The database will be managed by the coordination team in an anonymous way by means of the
      patient identifiers of the TMRO base.

      Enrichment of the base by the anonymous questionnaires filled by the patients and the
      complementary data transmissions of the centers on anonymised files.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">September 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Description of the characteristics of the patients of less than 45 years having a fertility-sparing surgery for borderline ovarian tumors</measure>
    <time_frame>December 2018</time_frame>
    <description>Univariate and multivariate analysis on patients modalities of care and fertility , through medical history and questionnaires (study based on patients who were included in the previous study &quot;Observatoire Sur Les Tumeurs Malignes Rares de l'Ovaire&quot; (TMRO french network)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validation of a nomogram as an information medium to the patients concerned on their chance of alive birth according to their personal characteristics</measure>
    <time_frame>December 2018</time_frame>
    <description>Test of a published fertility prognostic tool in this population. Estimation of the precision of the estimation of alive birth in our cohort will be done by determining the difference between predicted live birth and observed rate of live birth.</description>
  </secondary_outcome>
  <enrollment type="Actual">176</enrollment>
  <condition>Borderline Ovarian Tumors</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Fertility-sparing surgery for patients with borderline ovarian tumor and fertility.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with history of Borderline Ovarian Tumor (BOT).

          -  Women who have had first a fertility-sparing surgery.

          -  Women old enough to procreate (= 45 years) during their first surgery.

          -  Women having agreed to participate in the previous study &quot;Observatoire sur les Tumeurs
             Malignes Rares de l'Ovaire&quot; (TMRO).

          -  Women who have not expressed their opposition to the research.

        Exclusion Criteria:

          -  The patients who are not corresponding to the selection criteria are straightaway
             excluded from the retrospective database selected for the study (TMRO).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Delphine HEQUET, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean PERRIN</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli CALMETTES</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie, Paris</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Goerges POMPIDOU</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goupe Hospitalier Diaconesses Croix Saint-Simon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal Poissy - Saint-Germain</name>
      <address>
        <city>Poissy</city>
        <zip>78300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Saint-Cloud</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopole - Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine - Centre Alexis VAUTRIN</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>July 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Borderline Ovarian Tumor (BOT)</keyword>
  <keyword>Fertility-sparing surgery</keyword>
  <keyword>Gynecology</keyword>
  <keyword>Oncology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

